Anticonvulsant Recalled

McKesson Corporation, which does business as McKesson Drug Company, is recalling a single lot of levetiracetam tablets because of an incorrect barcode printed on the product’s label.

The error “could result in some units being read as naproxen tablets 500 mg,” the June 16, 2021, US Food and Drug Administration (FDA) Enforcement Report stated. “Product is labeled correctly as levetiracetam.”

The voluntary recall affects levetiracetam tablets, 250 mg, 100-tablet (10 x 10) boxes (NDC 63739-795-10), from lot 0000124916 (Exp. 9/30/22). The tablets were manufactured by Aurobindo Pharma Limited, Hyderabad, India, and distributed by McKesson Corporation, Memphis, TN, to sites throughout the United States.

McKesson Corporation initiated the recall May 26, 2021. On June 15, 2021, the FDA designated the recall Class III. Under the recall classification, use of the affected tablets is not likely to cause harm.

Levetiracetam is a prescription medication used to treat seizures in patients with epilepsy.